<SEC-DOCUMENT>0001193125-24-139703.txt : 20240516
<SEC-HEADER>0001193125-24-139703.hdr.sgml : 20240516
<ACCEPTANCE-DATETIME>20240515211557
ACCESSION NUMBER:		0001193125-24-139703
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240515
FILED AS OF DATE:		20240516
DATE AS OF CHANGE:		20240515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		24953351

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d787076d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as May 15, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d787076dex991.htm">Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May 15, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d787076dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g787076dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Presents Data from Safety <FONT STYLE="white-space:nowrap">Lead-in</FONT> Phase of <FONT
STYLE="white-space:nowrap">AIPAC-003</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>at ESMO Breast 2024 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy
achieved during combination treatment with 90mg efti and paclitaxel </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ongoing complete response has been maintained since the patient started treatment with efti monotherapy
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti + paclitaxel combination continues to be well tolerated with a favourable safety profile
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First-ever 90mg dosing leads to higher maximum concentration of efti, as well as pharmacologically active level
up to 96 hours after administration </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Data from randomized Phase II portion of study expected in CY2024 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; May</B><B></B><B>&nbsp;15, 2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces encouraging efficacy, safety, and pharmacodynamic data from the
safety <FONT STYLE="white-space:nowrap">lead-in</FONT> of the <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> Phase II/III trial presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2024 Congress. This <FONT
STYLE="white-space:nowrap">lead-in</FONT> represents the first ever 90mg dosing of eftilagimod alpha (&#147;efti&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist, given in combination with weekly
paclitaxel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Efficacy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The poster titled
<I>&#147;Testing a higher dose (90 mg s.c.) of eftilagimod alpha, a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein, in metastatic breast cancer patients receiving weekly paclitaxel in
<FONT STYLE="white-space:nowrap">AIPAC-003&#148;</FONT></I> details positive results in six metastatic breast cancer (MBC) patients, who exhausted endocrine therapy including cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The data shows a
confirmed 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate, with three patients having stable disease as best overall response per RECIST 1.1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Complete Response Patient Case Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patient with a
confirmed complete response (CR) was diagnosed with triple-negative breast carcinoma (TNBC) in 2019 and has failed multiple lines of therapy including a CDK 4/6 inhibitor for ER+/PR+ metastasis. During the immuno-oncology (IO)-chemotherapy treatment
of efti and paclitaxel, this patient achieved a partial response (PR) that subsequently turned into a CR. This patient&#146;s ongoing CR has been maintained since stopping paclitaxel and being treated with efti monotherapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safety&nbsp;&amp; Pharmacodynamic Effects </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">lead-in</FONT> has also shown that the first-ever 90mg efti dosing in combination with weekly paclitaxel continues to be well tolerated with a favourable safety profile. As of the data
<FONT STYLE="white-space:nowrap">cut-off</FONT> (April 3), no dose-limiting toxicities and no treatment-emergent adverse events of grade 3 or higher severity were recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 90mg efti dosing leads to a higher maximum concentration of efti in the blood as compared to lower efti doses in past clinical trials, and efti remains
detectable at a pharmacologically active level (<U>&gt;</U>1 ng/mL) up to 96 hours after administration. Pharmacodynamic effects also showed an increase of circulating levels of immune cells such as CD8 &amp; CD4 T cells and plasma Th1 biomarker
levels. All patients in the <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> safety <FONT STYLE="white-space:nowrap">lead-in</FONT> had a <FONT STYLE="white-space:nowrap">&#8805;1.4-fold</FONT> change in interferon-gamma <FONT
STYLE="white-space:nowrap">(IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>) and ~83% had a <FONT STYLE="white-space:nowrap">&#8805;1.4-fold</FONT> change in CXCL10 after a single 90mg efti dose. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g787076dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Serafin Morales Murillo, University Hospital Arnau de Vilanova, Lleida, Spain, and <FONT
STYLE="white-space:nowrap">AIPAC-003</FONT> investigator stated, &#147;It is encouraging to see the high efti dose of 90mg with weekly paclitaxel continue to be safe and well tolerated in these metastatic breast cancer patients. It is also positive
at this early stage to see high response and disease control rates, including a complete response, in these patients who have unfortunately all seen their cancers progress after endocrine therapy including CDK 4/6 inhibitors. We are looking forward
to further data emerging from this study.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The randomized Phase II portion of the trial, which will include up to 58 evaluable patients, is underway
and focused on whether 90mg efti dosing is more efficacious than 30mg dosing. This portion of the trial has enrolled 35 patients to date. Importantly, the determination of the optimal dose in <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> is
directly tied to the <U>FDA&#146;s Project Optimus</U> initiative and is relevant for the entire efti program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further data updates in terms of safety
and efficacy from <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> are expected in CY2024. The ESMO Breast 2024 poster will be available on the <U>Posters &amp; Publications</U> section of Immutep&#146;s website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells,
CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further
boost the immune system&#146;s ability to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug
Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte
Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to
leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow
Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>c.strong@morrowsodali.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g787076dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g787076dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@!"0OMVHV#;TB12W$%O&\LTT<,42EWDE81QHBC)9G; 50!DDG@4I-07O/
ME2[D2G"G!5)R48=&W9'!2?%?X<17'V5O&GASS%;8=NIV[1*0<'=.K&)<>[]J
MYUC,+?E5:-UTN>?+.<KA+DEC:49+I=_Y'>6]U;7<,4]K/#<031K+#-!(LL4L
M; %)(Y$)5T(((8$@@C%=$91DKQ::Z69Z$)PG",Z<E*$E>,HNZMY-$X/^?I3V
M\K%KRV"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!
MC\+]/Z47Y>E_(37GRI;^G4^(OC!KGB7X@ZIXLT+P_>6\/A[P(J)J.F_:F@O-
M=U &9+GR;6-2U\MO+!-$L#%5W1E^6DCV^!CYU:U25.G/E5/1J_7T/SW/,3BL
M?7KX?"U?9TL)[JBG;F>VBOK;\$>7:=\'?',OAV_UNY\*WK++;VC:6SWMO:W,
M(>:-IKZ;3W;S6MUMPY*R)&R@JW(!<<4,#5]G^\IRW3NM[+KZ'CT.'\P^J5*U
M:$XZKF;W]F_B:UOL>N>"_'OA;P+XR\->%_!^MZAK'A?6X8-/UR*]:X>TT[Q!
M/,+>WO=*:YMX3&LDQ59UB4PLL@="2H-=N'Q%"C7ITZ%1RB_==WHGI^.A]!@L
MSPF78S X# 575P=2FH2C)MR5:\=;OHDI)^OH?:*$\=A@^WICCZ5[[>JMM:Y]
MT_C7+\*7XZ$E PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?0?H!7UB^ST21^PQT\MA]44% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MO=W]VQBMK=99H[>)I),?*&FEC0>[CUK6UOD=O5QZQ5VO(Q_"WC[P9XV^V_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MAI]W$TNE7ERS?,]WM@NH)';+.;02.2\C4?H'Z'U'0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M:  J#VZ?IB@ "A>@QC^G% "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!#Y\/\
MST48]P,8J>>"=N9772YE[>C_ ,_H*W]Y!Y\/_/1?S%/FC_,OO0>WH?\ /Z'_
M ($@\^'_ )Z+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?
M^!(//A_YZ+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\
M@2#SX?\ GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X
M$@\^'_GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!
M(//A_P">B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2
M#SX?^>B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@
M\^'_ )Z+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(/
M/A_YZ+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#S
MX?\ GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X$@\^
M'_GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!(//A
M_P">B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2#SX?
M^>B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@\^'_
M )Z+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(//A_Y
MZ+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#SX?\
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M//A_YZ+^8HYH_P R^]![>A_S^A_X$@-Q"/\ EHOY@T<T?YE]XGB*"_Y>Q_\
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M^2K]S#^R<_\ ^@?$_<_\P_X5A\3O^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\
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MOW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'U;'?R5?N8?V3G_\
MT#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\P_X5A\3O
M^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"CXE_\ Y_
M\:/JV._DJ_<P_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\E7[F']DY
M_P#] ^)^Y_YA_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\ H'Q/W/\
MS#_A6'Q._P"A1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/B=_T*/B7
M_P  Y_\ &CZMCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'
MU;'?R5?N8?V3G_\ T#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\
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M^%8?$[_H4?$O_@'/_C1]6QW\E7[F']DY_P#] ^)^Y_YA_P *P^)W_0H^)?\
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M<_\ ^@?$_<_\P_X5A\3O^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\
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M'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\P_X5A\3O^A1\2_\
M@'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"CXE_\ Y_\:/JV._D
MJ_<P_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\E7[F']DY_P#] ^)^
MY_YA_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\ H'Q/W/\ S#_A6'Q.
M_P"A1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/B=_T*/B7_P  Y_\
M&CZMCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'U;'?R5?N
M8?V3G_\ T#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\
MP_X5A\3O^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"
MCXE_\ Y_\:/JV._DJ_<P_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\
ME7[F']DY_P#] ^)^Y_YA_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\
MH'Q/W/\ S#_A6'Q._P"A1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/
MB=_T*/B7_P  Y_\ &CZMCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\
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CX8'H* YGW?WA@>@H#F?=_>&!Z#CVZ8J9;>A4-79ZI=&?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
